{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:33:35Z","timestamp":1793136815697,"version":"4.5.0"},"reference-count":33,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2024,7,31]]},"DOI":"10.7883\/yoken.jjid.2023.389","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T22:12:39Z","timestamp":1706652759000},"page":"213-219","source":"Crossref","is-referenced-by-count":5,"title":["Biofilm Eradication of &lt;i&gt;Stenotrophomonas maltophilia&lt;\/i&gt; by Levofloxacin and Trimethoprim-Sulfamethoxazole"],"prefix":"10.7883","volume":"77","author":[{"given":"Jos\u00e9 Mauricio Del","family":"R\u00edo-Chac\u00f3n","sequence":"first","affiliation":[{"name":"Laboratory of Ecology, School of Medicine, University of Colima, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabi\u00e1n","family":"Rojas-Larios","sequence":"additional","affiliation":[{"name":"Laboratory of Ecology, School of Medicine, University of Colima, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bocanegra-Ibarias","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospital Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez and School of Medicine, Autonomous University of Nuevo Le\u00f3n, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Salas-Trevi\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospital Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez and School of Medicine, Autonomous University of Nuevo Le\u00f3n, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Espinoza-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Laboratory of Ecology, School of Medicine, University of Colima, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Camacho-Ortiz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospital Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez and School of Medicine, Autonomous University of Nuevo Le\u00f3n, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Flores-Trevi\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospital Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez and School of Medicine, Autonomous University of Nuevo Le\u00f3n, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Mojica MF, Humphries R, Lipuma JJ, et al. Clinical challenges treating <i>Stenotrophomonas maltophilia<\/i> infections: an update. JAC Antimicrob Resist. 2022;4:dlac040.","DOI":"10.1093\/jacamr\/dlac040"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Herrera-Heredia SA, Pezina-Cantu C, Garza-Gonzalez E, et al. Risk factors and molecular mechanisms associated with trimethoprim-sulfamethoxazole resistance in <i>Stenotrophomonas maltophilia<\/i> in Mexico. J Med Microbiol. 2017;66:1102-1109.","DOI":"10.1099\/jmm.0.000550"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chang YT, Lin CY, Chen YH, et al. Update on infections caused by <i>Stenotrophomonas maltophilia<\/i> with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015;6:893.","DOI":"10.3389\/fmicb.2015.00893"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gales AC, Seifert H, Gur D, et al. Antimicrobial susceptibility of <i>Acinetobacter calcoaceticus-Acinetobacter baumannii<\/i> complex and <i>Stenotrophomonas maltophilia<\/i> clinical isolates: results from the SENTRY Antimicrobial Surveillance Program (1997\u20132016). Open Forum Infect Dis. 2019;6:S34-S46.","DOI":"10.1093\/ofid\/ofy293"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gibb J, Wong DW. Antimicrobial treatment strategies for <i>Stenotrophomonas maltophilia<\/i>: a focus on novel therapies. Antibiotics (Basel). 2021;10:1226.","DOI":"10.3390\/antibiotics10101226"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Spencer HK, Spitznogle SL, Borjan J, et al. An overview of the treatment of less common non-lactose-fermenting gram-negative bacteria. Pharmacotherapy. 2020;40:936-951.","DOI":"10.1002\/phar.2447"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Flores-Trevi\u00f1o S, Bocanegra-Ibarias P, Camacho-Ortiz A, et al. <i>Stenotrophomonas maltophilia<\/i> biofilm: its role in infectious diseases. Expert Rev Anti Infective Ther. 2019;17:877-893.","DOI":"10.1080\/14787210.2019.1685875"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Brooke JS. Advances in the microbiology of <i>Stenotrophomonas maltophilia<\/i>. Clin Microbiol Rev. 2021;34:e0003019.","DOI":"10.1128\/CMR.00030-19"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Olsen I. Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis. 2015;34:877-886.","DOI":"10.1007\/s10096-015-2323-z"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rhoads DD. <i>Stenotrophomonas maltophilia<\/i> susceptibility testing challenges and strategies. J Clin Microbiol. 2021;59:e0109421.","DOI":"10.1128\/JCM.01094-21"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Montoya-Hinojosa E, Bocanegra-Ibarias P, Garza-Gonz\u00e1lez E, et al. Discrimination of biofilm-producing <i>Stenotrophomonas maltophilia<\/i> clinical strains by matrix-assisted laser desorption ionization-time of flight. PLoS One. 2020;15:e0244751.","DOI":"10.1371\/journal.pone.0244751"},{"key":"12","unstructured":"12. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 31st ed. Document M100. Berwyn, PA, USA: CLSI; 2021."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ali L, Khambaty F, Diachenko G. Investigating the suitability of the Calgary Biofilm Device for assessing the antimicrobial efficacy of new agents. Bioresour Technol. 2006;97:1887-1893.","DOI":"10.1016\/j.biortech.2005.08.025"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ceri H, Olson ME, Stremick C, et al. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771-1776.","DOI":"10.1128\/JCM.37.6.1771-1776.1999"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Villarreal-Salazar V, Bocanegra-Ibarias P, Villarreal-Trevi\u00f1o L, et al. Improvement of antimicrobial susceptibility testing in biofilm-growingcoagulase-negative <i>Staphylococcus hominis<\/i>. J Microbiol Methods. 2022;198:106493.","DOI":"10.1016\/j.mimet.2022.106493"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Santos Carvalhais BE, Souza ESC, Dos Santos KV. Effect of antimicrobials on <i>Stenotrophomonas maltophilia<\/i> biofilm. Future Microbiol. 2021;16:83-93.","DOI":"10.2217\/fmb-2020-0115"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Duan Z, Qin J, Li C, et al. Clinical and molecular epidemiology of <i>Stenotrophomonas maltophilia<\/i> in pediatric patients from a Chinese teaching hospital. Front Cell Infect Microbiol. 2020:10:411.","DOI":"10.3389\/fcimb.2020.00411"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Menetrey Q, Sorlin P, Jumas-Bilak E, et al. <i>Achromobacter xylosoxidans<\/i> and <i>Stenotrophomonas maltophilia<\/i>: emerging pathogens well-armed for life in the cystic fibrosis patients\u2019 lung. Genes(Basel). 2021;12:610.","DOI":"10.3390\/genes12050610"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Flores-Trevi\u00f1o S, Guti\u00e9rrez-Ferman JL, Morf\u00edn-Otero R, et al. <i>Stenotrophomonas maltophilia<\/i> in Mexico: antimicrobial resistance, biofilm formation and clonal diversity. J Med Microbiol. 2014;63:1524-1530.","DOI":"10.1099\/jmm.0.074385-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chong WH, Saha BK, Ananthakrishnan R, et al. State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. Infection. 2021;49:591-605.","DOI":"10.1007\/s15010-021-01602-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Saleh RO, Hussen BM, Mubarak SM, et al. High diversity of virulent and multidrug-resistant <i>Stenotrophomonas maltophilia<\/i> in Iraq. Gene Reports. 2021;23:101124.","DOI":"10.1016\/j.genrep.2021.101124"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mori M, Tsunemine H, Imada K, et al. Life-threatening hemorrhagic pneumonia caused by <i>Stenotrophomonas maltophilia<\/i> in the treatment of hematologic diseases. Ann Hematol. 2014;93:901-911.","DOI":"10.1007\/s00277-014-2028-x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Cruz-C\u00f3rdova A, Mancilla-Rojano J, Luna-Pineda VM, et al. Molecular epidemiology, antibiotic resistance, and virulence traits of <i>Stenotrophomonas maltophilia<\/i> strains associated with an outbreak in a Mexican tertiary care hospital. Front Cell Infect Microbiol. 2020;10:50.","DOI":"10.3389\/fcimb.2020.00050"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Bostanghadiri N, Ardebili A, Ghalavand Z, et al. Antibiotic resistance, biofilm formation, and biofilm-associated genes among <i>Stenotrophomonas maltophilia<\/i> clinical isolates. BMC Res Notes. 2021;14:151.","DOI":"10.1186\/s13104-021-05567-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Wu RX, Yu CM, Hsu ST, et al. Emergence of concurrent levofloxacin- and trimethoprim\/sulfamethoxazole-resistant <i>Stenotrophomonas maltophilia<\/i>: risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan. J Microbiol Immunol Infect. 2022;55:107-113.","DOI":"10.1016\/j.jmii.2020.12.012"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wang Y, Li Y, Zhao J, et al. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria. Ann Transl Med. 2022;10:261.","DOI":"10.21037\/atm-22-889"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kullar R, Wenzler E, Alexander J, et al. Overcoming <i>Stenotrophomonas maltophilia<\/i> resistance for a more rational therapeutic approach. Open Forum Infect Dis. 2022;9:ofac095.","DOI":"10.1093\/ofid\/ofac095"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Passerini de Rossi B, Garc\u00eda C, Calenda M, et al. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of <i>Stenotrophomonas maltophilia<\/i> isolates from patients with device-associated infections. Int J Antimicrob Agents. 2009;34:260-264.","DOI":"10.1016\/j.ijantimicag.2009.02.022"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sun E, Liang G, Wang L, et al. Antimicrobial susceptibility of hospital acquired <i>Stenotrophomonas maltophilia<\/i> isolate biofilms. Braz J Infect Dis. 2016;20:365-373.","DOI":"10.1016\/j.bjid.2016.04.002"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Wang A, Wang Q, Kudinha T, et al. Effects of fluoroquinolones and azithromycin on biofilm formation of <i>Stenotrophomonas maltophilia<\/i>. Sci Rep. 2016;6:29701.","DOI":"10.1038\/srep29701"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Pompilio A, Crocetta V, Verginelli F, et al. In vitro activity of levofloxacin against planktonic and biofilm <i>Stenotrophomonas maltophilia<\/i> lifestyles under conditions relevant to pulmonary infection in cystic fibrosis, and relationship with SmeDEF multidrug efflux pump expression. FEMS Microbiol Lett. 2016;363:fnw145.","DOI":"10.1093\/femsle\/fnw145"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Di Bonaventura G, Spedicato I, D&apos;Antonio D, et al. Biofilm formation by <i>Stenotrophomonas maltophilia<\/i>: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother. 2004;48:151-160.","DOI":"10.1128\/AAC.48.1.151-160.2004"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Bio\u010danin M, Madi H, Vasiljevi\u0107 Z, et al. Temperature, pH and trimethoprim-sulfamethoxazole are potent inhibitors of biofilm formation by <i>Stenotrophomonas maltophilia<\/i> clinical isolates. Pol J Microbiol. 2017;66:433-438.","DOI":"10.5604\/01.3001.0010.6996"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/77\/4\/77_JJID.2023.389\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T04:18:06Z","timestamp":1722053886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/77\/4\/77_JJID.2023.389\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2023.389","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"article-number":"JJID.2023.389"}}